Vida Pharmacal today announced that its innovative amiodarone + itraconazole drug for treating Chagas disease in dogs has received Priority Zoonotic Animal Drug (PZAD) designation from the U.S. Food & Drug Administration (FDA). Vida is the first company to receive a PZAD designation for Chagas disease treatment.
Vida Pharmacal today announced the first cure for canine Chagas disease. Its multicenter field study, Successful Treatment of Canine Chagas Disease, was published in the prestigious Journal of the American Veterinary Medical Association, August 1, 2019.
Vida Pharmacal, the first pharmaceutical company devoted to developing, marketing, and distributing a treatment for Chagas disease in veterinary patients, today announced its official launch.